The Wall Street Journal

The obesity market is growing just fine – but investors want to know what’s next

The obesity market is growing just fine – but investors want to know what’s next
On paper, Ozempic owner Novo has an extensive pipeline, with several next-generation drugs in development.
The Wall Street Journal
By David WainerInvestors in the obesity drug market can breathe a sigh of relief – but not for long.On Wednesday, Novo Nordisk calmed fears of slowing demand, projecting a robust 20% increase in companywide sales at the midpoint of its 2025 guidance. While slightly slower than last year’s growth, that pace remains impressive in the world of pharmaceutical companies. Eli Lilly, meanwhile, on Thursday confirmed an earlier projection of about 32% revenue growth this year.After months of choppy stock performance driven by fears of a mar...

More Finance

Grenon seeks to end ‘futile’ NZME board stoush
Finance

Grenon seeks to end ‘futile’ NZME board stoush

It's time for the current board to fold 'em, says coup orchestrator. 

Pattrick Smellie 26 Mar 2025
Wow. It’s all basketball!
Finance

Wow. It’s all basketball!

US investment in basketball is lapping at our shores in more ways than one.

Pattrick Smellie 25 Mar 2025
FMA files criminal charges against David McEwen
Finance

FMA files criminal charges against David McEwen

New Zealand’s financial watchdog has filed criminal charges against former financial adviser David McEwen for allegedly failing to comply with a stop order, which prevented him from contacting potential investors.The Financial Markets Authority (FMA) had made a permanent stop ord...

Staff reporters 18 Mar 2025
FNZ employee shareholders revolt over latest capital raise
Finance Exclusive

FNZ employee shareholders revolt over latest capital raise

Long-standing employees believe new raise halves their holdings.

Victoria Young 14 Mar 2025